Skip to main content
Utility Menu
Patients
Healthcare Providers
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Patients
Healthcare Providers
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Facioscapulohumeral muscular dystrophy
Myotonic dystrophy type 1
Our Science
siRNA
RNA Platform
Gene Therapy
Manufacturing
Strategic Partnerships
Investigator-Initiated Studies
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Limb-girdle muscular dystrophy (LGMD)
Community Letter: SRP-9001 Advisory Committee Date is Announced
Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023
Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
A conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Measurements used in clinical trials for Duchenne muscular dystrophy – an overview
Pagination
First page
« First
Previous page
‹ Previous
…
Page
35
Page
36
Page
37
Page
38
Page
39
Page
40
Current page
41
Page
42
Page
43
Next page
Next ›
Last page
Last »
